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ANALYSIS
Drugs for psychiatric problems are pre­
scribed on the assumption that they mostly 
act against neurochemical substrates of dis­
orders or symptoms. In this article we ques­
tion that assumption, proposing that drugs’ 
action be viewed rather as producing altered, 
drug induced states, a view we have called 
the drug centred model of action. We believe 
that this view accords better with the avail­
able evidence. It may also allow patients to 
exercise more control over decisions about 
the value of pharmacotherapy, helping to 
move mental health treatment in a more 
collaborative direction.
Assumptions about mode of action
The widespread use of psychiatric drugs is jus­
tified by the idea that they work by correcting, 
or helping to correct, underlying biological 
abnormalities that produce particular psy­
chiatric symptoms. We have called this view 
the disease centred model of psychiatric drug 
action (table). Most drugs used in medicine 
can be understood as working according to 
a disease centred model—even analgesics, for 
example, work by acting on the physiological 
mechanisms that produce pain. In psychia­
try, the disease centred model is reflected in 
the names of the major drug classes: antide­
pressants are believed to reverse biochemi­
cal pathways that give rise to symptoms of 
depression and antipsychotics are thought to 
act on mechanisms that produce psychotic 
symptoms. From this viewpoint, the therapeu­
tic actions of drugs (their actions on disease 
processes) can be distinguished from other 
effects, accordingly termed side effects.
An alternative, drug centred model of drug 
action, stresses that psychiatric drugs are, 
first and foremost, psychoactive drugs. They 
induce complex, varied, often unpredictable 
physical and mental states that patients typi­
cally experience as global, rather than distinct 
therapeutic effects and side effects (table). 
Drugs may be useful because some altered 
states can suppress the manifestations of cer­
tain mental disorders.
The disease centred model of drug action 
developed in the 1950s and 1960s and replaced 
a drug centred understanding of how psychi­
atric drugs worked.1 For example, the early 
investigators of neuroleptic or antipsychotic 
drugs suggested that they worked by inducing 
a neurological syndrome consisting of physi­
cal restriction and mental symptoms such 
as cognitive slowing, apathy, and emotional 
flattening, which resembled Parkinson’s dis­
ease.2 These effects also reduced the intensity 
of psychotic symptoms. Thus,  extrapyramidal 
effects, and their con­
joined mental effects, 
were not regarded 
as side effects but as 
the mechanism by 
which the drugs pro­
duced their intended 
 outcome.3 
Inducing overt 
parkinsonism has 
long been thought 
unnecessary to pro­
duce a therapeutic 
effect, yet there has 
been little consider­
ation of the mental 
alterations produced 
by neuroleptic drugs 
and just how these 
might interact with 
psychotic symp­
toms. Some modern 
commentators have 
suggested that the 
emotional indifference induced by neurolep­
tics accounts for their therapeutic effects,4 and 
empirical research supports this position.5 
Overall, the drug centred model suggests 
looking more closely at how psychological 
alterations produced by psychiatric drugs 
interact with the experiences of distress and 
psychosocial disability that lead people to seek 
clinical help.6
Evidence on psychiatric drug action
Both models help clarify possible mecha­
nisms of drug action and need not be mutu­
ally exclusive. However, the neglect of the 
psychoactive effects of psychiatric drugs has 
made it difficult to establish disease specific 
actions. For example, placebo controlled tri­
als are not designed to distinguish whether 
observed outcomes occur because of the 
drug’s action on an underlying pathological 
process or as a consequence of being in an 
altered state.  Psychoactive effects, including 
sedation, psychomotor slowing, activation, 
and altered sense perception, could have an 
effect on the symptoms of distress in countless 
disorders and be distinguished from effects 
associated with inert placebo.6 Any drug with 
sedative properties, for example, will modify 
disturbances of sleep and arousal found in 
many psychiatric 
conditions and in 
the disorder specific 
rating scales used in 
clinical trials.
A second di f ­
ficulty has been a 
paucity of realistic 
trials that use active 
placebos or compare 
drugs believed to be 
disorder specific 
(according to current 
diagnostic classifica­
tions or theories) with 
other drugs known to 
exert some psycho­
active effects. Early 
trials comparing 
chlorpromazine and 
barbiturates favoured 
chlorpromazine, but 
comparisons with 
benzodiazepines give 
mixed results,7 and a trial using opium as a 
comparator found no difference.8 However, 
although evidence of the superiority of anti­
psychotics might imply disease specific effects, 
superior effects can also be explained within a 
drug centred framework. This view suggests 
that the characteristic psychomotor and emo­
tional restriction induced by antipsychotics is 
more effective at suppressing psychotic agita­
tion than other sedatives, as proposed by the 
early investigators.2
Drugs not normally considered to be anti­
depressants, including antipsychotics, benzo­
diazepines, and stimulants, have been found 
to have comparable effects to antidepressants 
in people with depression.9 Comparisons 
of lithium with antipsychotics and benzodi­
azepines have not confirmed its superiority to 
treat mania or affective psychosis.10 Although 
one study suggested some differential effect on 
particular symptoms,11 others have not.12
Biochemical aetiological theories such as 
the dopamine theory of schizophrenia or 
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psychosis and the monoamine hypothesis of 
depression seem to support a disease centred 
view of drug action, although their strongest 
support remains the presumed specificity of 
drug treatment. Proponents of the dopamine 
hypothesis argue that antipsychotics exert their 
therapeutic action by correcting an underly­
ing dopamine dysregulation.13 However, little 
evidence suggests that any abnormality of the 
dopamine system is specific to psychosis and 
not accounted for by other factors associated 
with dopamine activity, such as increased 
arousal or stress. That some effective antipsy­
chotic drugs such as clozapine have relatively 
weak actions on dopamine receptors also 
seems to contradict the theory.14 
Evidence for the monoamine hypothesis, 
which states that antidepressants work by 
countering a deficiency of noradrenaline or 
serotonin activity, is also questionable. Many 
different investigations of the drugs’ metabo­
lites and receptors in depressed people and 
postmortem examinations have produced no 
reliable demonstration of such a deficiency.15
Generally, there have been few attempts to 
evaluate the dominant, disease centred expla­
nation for drug action in psychiatry because 
few people realise that an alternative explana­
tion exists.1 The little available evidence does 
not yet provide compelling grounds to accept 
the disease centred model.
Drug centred model in research
There has been little systematic exploration 
of the full range of psychoactive and physical 
effects produced by psychiatric drugs. This 
information is typically obscured by short 
clinical trials that focus on narrow complaints 
and outcomes and relegate 
other effects to the status of 
side effects.16 There is also 
a paucity of research on 
the often unpredictable, 
long term effects of drugs, 
the consequences of drug withdrawal, and the 
nature of the large black box presently called 
the placebo effect.
For example, the nature of the subjec­
tive state induced by taking selective serot­
onin reuptake inhibitors (SSRIs), and how 
it interacts with expectancy effects, remains 
unclear. Volunteer studies  suggest these drugs 
may have concurrent sedative and activat­
ing or stimulant effects,17 and some research 
 indicates they reduce emotional responsive­
ness, but this has not been confirmed.18 How 
they cause suicidal ideation, if they do, is also 
not established. Similarly, few data exist about 
the subjective effects produced by second 
 generation  antipsychotics, how they differ 
from each other, and whether they are simi­
lar to the effects  produced by older antipsy­
chotics. Obviously, this information is crucial 
if people are to make informed choices about 
whether these drugs are likely to improve 
their mental state and what price might be 
paid in return.
More comprehensive volunteer studies 
are needed to obtain data on the full range 
of effects of psychiatric drugs. It is also impor­
tant to pay attention to patients’ uncensored 
accounts of taking psychiatric drugs, avail­
able on the internet, for example. Clinical 
trials need to devise ways to explore patients’ 
experiences more directly than through clini­
cians’ diagnoses and symptom rating scales. 
Patients’ views also need to be collected after 
the drugs have been stopped, since many 
effects may be difficult to identify while in a 
drug induced state.
Implications for clinical practice
Messages conveyed in information leaflets 
and advertising campaigns have persuaded 
millions of people that mental disorders are 
caused by chemical imbalances that can be 
rectified by drugs.19 However, given the 
paucity of the evidence, we suggest that pre­
scribers should not present the drugs they 
prescribe for mental disorders as disease spe­
cific treatments. Psychiatric drugs might need 
renaming, to avoid the presumption of spe­
cificity built into labels like antidepressants 
and antipsychotics.
The drug centred 
model may change 
attitudes to psychiatric 
drugs and empower 
patients to be more 
involved in decisions about treatment. 
Whereas a disease centred model has a built­
in assumption that drug treatment is likely to 
be physiologically corrective and therefore 
beneficial, a drug centred model, by stress­
ing that drugs are extrinsic substances that 
alter how the body works, demands that 
the advantages and disadvantages of tak­
ing a drug be carefully weighed up and dis­
tinguished from the effects of treatment in 
general. Highlighting that psychiatric drugs 
are psychoactive substances allows people 
to judge for themselves what sort of drug 
induced effects might help them and what 
sort might not. Patients become the ultimate 
arbiters of the value of taking a particular 
drug and are encouraged to take an active 
role in adjusting drug regimens to suit their 
needs.
In the short term, for example, the cog­
nitive and emotional suppression described 
by people who have taken antipsychotic 
drugs may bring relief to someone trauma­
tised by intense psychotic experiences and 
allow  people to engage better with the world 
around them.20 However, after recovery from 
an acute episode, some people may decide 
that the costs of continued drug treatment 
are not outweighed by the reduction in the 
risk of relapse that long term treatment may 
produce. According to a drug centred model, 
therefore, non­ compliance may be a rational 
response to the effects of drugs, which pre­
scribers need to understand and accommo­
date rather than overcome.
People with depression are likely to 
respond differently to an offer of a drug 
intended to produce an altered state than a 
drug said to act on the underlying biological 
mechanism of depressive symptoms. Various 
 psychoactive drugs, such as antipsychotics 
and possibly SSRIs, may suppress the expe­
rience or expression of emotions, including 
feelings of depression, but it seems unlikely 
that many people would desire this kind of 
effect. On the other hand, some people with 
depression may find drugs with sedative 
effects, such as benzodiazepines and low dose 
tricyclic antidepressants, useful temporarily 
to bring relief from troubled sleep, anxiety, 
and agitation.
In this way, the drug centred model 
 provides a rationale for periodic rather 
than continuous drug use, to cope with 
There has been little systematic 
exploration of the full range of 
psychoactive and physical effects 
produced by psychiatric drugs
Models of psychiatric drug action
Disease centred model Drug centred model
Drugs correct an abnormal 
brain state
Drugs create an altered 
physical and mental state
Therapeutic effects arise 
from the action of drugs 
on an underlying disease 
process
Therapeutic effects are a 
consequence of being in an 
altered state
Main indication is the 
presence of a particular 
disease
Indication is the value of 
particular drug induced 
effects
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 exacerbations of symptoms or to palliate 
stressful environmental events and avoid the 
harm associated with long term use. It ques­
tions the use of complex drug cocktails, com­
monly prescribed in the United States, for 
example, based on the presumed fit between 
different drugs and multiple diagnoses given 
to a patient. It also allows doctors, patients, 
and people who know patients to properly 
monitor the full consequences of drug treat­
ment and engage in an ongoing dialogue 
about how it compares with alternative 
 interventions.
Medicine, as a whole, has started to rec­
ognise the importance of involving patients 
in decisions about their care. By highlighting 
the nature of psychiatric drugs as psychoac­
tive substances that produce altered states, 
the drug centred model may enable patients 
to participate more equally in the process 
of evaluating the likely effect of drug treat­
ment in their particular situation. A drug 
centred model also imposes a duty on the 
psychiatric research community to produce 
relevant, unbiased information about the 
range of effects that psychiatric drugs exert 
on thought, emotion, and all bodily systems, 
both during short term and long term use. At 
present, the influence of the disease centred 
model keeps the full range of effects of many 
drugs obscured, and hence neither doctors 
nor patients can make properly informed 
decisions about the risks and benefits of 
using them.
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PICTURE qUIz
A woman with tuberous sclerosis and acute onset  
right sided abdominal pain
1  Bilateral renal angiomyolipoma is the most likely cause of the masses seen in 
the figures. The computed tomography scans show that the renal parenchyma is 
abnormal, with enhancing vessels and low attenuation fat representing vascular 
and fatty components, respectively, within the angiomyolipoma.
2  The patient’s symptoms are caused by acute haemorrhage. Her physical condition 
and the imaging findings can be explained by haemorrhage from the vascular 
component of the angiomyolipoma. 
3  Selective renal arterial embolisation is the treatment of choice. Embolisation not 
only stops further bleeding but is less invasive than surgery and spares functioning 
renal tissue. After our patient was scanned, she immediately went to angiography 
for embolisation.
CASE REPoRT
A case of secondary amenorrhoea
1  This patient has Asherman’s syndrome, a condition 
characterised by scarring of the uterine cavity.
2  Hysteroscopy is recommended in a patient with 
these symptoms.
3  Hysteroscopically directed division of adhesions is 
the optimum treatment.
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